

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**PuraPharm**

**PURAPHARM CORPORATION LIMITED**

**培力農本方有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1498)**

**APPOINTMENT OF  
INDEPENDENT NON-EXECUTIVE DIRECTOR,  
CHAIRMAN OF THE AUDIT COMMITTEE,  
MEMBER OF THE REMUNERATION COMMITTEE AND  
MEMBER OF THE NOMINATION COMMITTEE; AND  
COMPLIANCE WITH THE LISTING RULES**

The board (the “**Board**”) of directors (the “**Director(s)**”) of PuraPharm Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, with effect from 29 August 2025, Dr. Hung Ting On, John (洪廷安) (“**Dr. Hung**”) was appointed as an independent non-executive Director, the chairman of the audit committee of the Board (the “**Audit Committee**”), the member of the remuneration committee of the Board (the “**Remuneration Committee**”) and the member of nomination committee of the Board (the “**Nomination Committee**”).

The biographical background of Dr. Hung is as follows:

Dr. Hung, aged 64, was a senior partner of Deloitte Asia Pacific stationed in Shanghai and has over 40 years of working experience in the field of audit, accounting and finance. Dr. Hung joined the London office of Deloitte in 1987 and was trained as a chartered accountant. Dr. Hung was admitted as a partner of Deloitte China in 1996. He has extensive experience in conducting financial audits, leading IPO projects, conducting financial due diligence, advising on merger and acquisitions and risk management. He served in various management roles in his career with Deloitte including the vice chairman of Deloitte China, the chairman of Deloitte Consulting China, the chairman of Global Chinese Services Group, member of the governing board of Deloitte China from 2008 to 2016 and from 2018 to 2020. He is currently the regional chair of Warwick Business School Alumni programme in China and Hong Kong and he sits on the advisory board of Warwick Business School. Prior to joining Deloitte, Dr Hung practiced as a civil and structural engineer for five years in Hong Kong and London. He was one of the Confederation of British Industry Overseas Scholars in Civil Engineering in 1985.

Dr. Hung was awarded a Doctor of Laws (honoris causa) in 2022 and obtained a Master of Business Administration (1987) from the University of Warwick in the United Kingdom. He possesses an associateship in civil and structural engineering from the Hong Kong Polytechnic University. He is a fellow member and past president of China Chapter of the Institute of Chartered Accountants in England and Wales. He is also a fellow member and former Shanghai President of the Australia CPA.

Dr. Hung confirms that (i) he is independent with regard to the independent criteria under Rule 3.13 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”); (ii) he does not have any past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Listing Rules) of the Company; and (iii) there are no other factors that may affect his independence at the time of his appointment. With the recommendation of the Nomination Committee, the Board considers that Dr. Hung is independent and satisfies all the independence criteria under Rule 3.13 of the Listing Rules.

Dr. Hung entered into a letter of appointment (“**Dr. Hung’s Letter of Appointment**”) with the Company for a fixed term of one year commencing on 29 August 2025 and shall be renewed and extended automatically by one year on the expiry of such initial term and on the expiry of every successive period of one year thereafter, unless terminated by either the Company or Dr. Hung giving at least three months’ written notice of non-renewal before the expiry of the then existing term, subject to the rotation, removal, vocation, termination, retirement and re-election in accordance with Dr. Hung’s Letter of Appointment. Dr. Hung shall hold office until the next following annual general meeting of the Company (the “**AGM**”) and shall then be eligible for re-election by the shareholders of the Company at the AGM pursuant to article 112 of the articles of association of the Company (the “**Articles**”) and thereafter subject to retirement by rotation at least once every three years in accordance with article 108(a) of the Articles.

As an independent non-executive Director, the chairman of the Audit Committee and member of the Remuneration Committee and the Nomination Committee of the Company, Dr. Hung is entitled to an annual remuneration of HK\$200,000 payable by quarterly instalment in accordance with Dr. Hung’s Letter of Appointment. Dr. Hung’s remuneration package is determined by the Board according to the Group’s policy on the Directors’ and senior management’s remuneration.

As at the date of this announcement, Dr. Hung does not have any interest in any shares, underlying shares or debenture of the Company and/or its associated corporation within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Dr. Hung does not have any relationship with any directors, senior management or substantial or controlling shareholders of the Company (as defined in the Listing Rules), and he does not hold any position in the Company or any of its subsidiaries.

Save as disclosed herein, the Board is not aware of any other matter relating to the appointment of Dr. Hung that needs to be brought to the attention of the shareholders of the Company and does not have any information required to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

The Board would like to express its warmest welcome to Dr. Hung in joining the Board and his new appointment as the chairman of the Audit Committee, the member of the Remuneration Committee and the member of the Nomination Committee.

## **COMPLIANCE WITH THE LISTING RULES**

Reference is made to the announcement of the Company on 4 July 2025 in relation to the non-compliance of Rule 3.10(1), Rule 3.10(2) Rule, Rule 3.21, Rule 3.25, and Rule 3.27A of the Listing Rules. Following the appointment of Dr. Hung as an independent non-executive Director, the chairman of the Audit Committee, the member of the Remuneration Committee and the member of the Nomination Committee, the Company has re-complied with the requirements of Rule 3.10(1), Rule 3.10(2) Rule, Rule 3.21, Rule 3.25, and Rule 3.27A of the Listing Rules.

By order of the Board  
**PURAPHARM CORPORATION LIMITED**  
**Chan Yu Ling, Abraham**  
*Chairman and Executive Director*

Hong Kong, 29 August 2025

*As at the date of this announcement, the executive Directors are Mr. Chan Yu Ling, Abraham, Ms. Man Yee Wai, Viola and Dr. Tsoi Kam Biu, Alvin; the non-executive Director is Mr. Leung Stephen Kwok Keung; and the independent non-executive Directors are Dr. Hung Ting On, John, Dr. Leung Lim Kin, Simon and Prof. Tsui Lap Chee.*